Next Article in Journal
The Involvement of Serotonin in the Obesity Pathway—A Last Decade Systematic Review of the Literature
Previous Article in Journal
Novel SCYL2 Mutations and Arthrogryposis Multiplex Congenita 4: Case Report and Review of the Literature
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 26
Issue 7
10.3390/ijms26073078
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

GAS5 rs145204276 Ins/Del Polymorphism Is Associated with CRC Susceptibility in a Romanian Population †

by
Cecil Sorin Mirea
1,2,‡,
Michael Schenker
3,‡,
Bianca Petre-Mandache
4,*,
Mihai-Gabriel Cucu
5,6,*,
Georgiana-Cristiana Camen
7,
Ionică Daniel Vîlcea
1,2,
Bogdan Cristian Albu
2,4,
Cosmin Vasile Obleagă
1,2,
Mihai Călin Ciorbagiu
1,2,
Ioana Streață
5,6,
Răzvan Mihail Pleșea
5,6,
Anca-Lelia Riza
5,6 and
Florin Burada
5,6
1
Department of Surgery, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
2
Department of Surgery, Emergency Clinical County Hospital, 200642 Craiova, Romania
3
Department of Oncology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
4
Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
5
Laboratory of Human Genomics, University of Medicine and Pharmacy of Craiova, 200638 Craiova, Romania
6
Regional Centre of Medical Genetics Dolj, Emergency Clinical County Hospital Craiova, 200642 Craiova, Romania
7
Department of Radiology and Medical Imaging, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
*
Authors to whom correspondence should be addressed.
†
This article is a revised and expanded version of a paper entitled The GAS5 rs145204276 ins/del polymorphism is associated with increased susceptibility to colorectal cancer, which was presented at 55th European-Society-of-Human-Genetics (ESHG) Conference, Vienna, Austria, 11–14 June 2022.
‡
These authors contributed equally to this work.
Int. J. Mol. Sci. 2025, 26(7), 3078; https://doi.org/10.3390/ijms26073078
Submission received: 30 January 2025 / Revised: 18 March 2025 / Accepted: 24 March 2025 / Published: 27 March 2025
(This article belongs to the Special Issue Innovative Technologies in the Study and Understanding of Colorectal Tumorigenesis: Challenges and Opportunities)
Review Reports Versions Notes

Abstract

Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality, influenced by both genetic and epigenetic factors. Long non-coding RNAs (lncRNAs) such as GAS5 and CASC8 have been implicated in cancer susceptibility. This study aimed to assess the association of GAS5 rs145204276 ins/del and CASC8 rs10505477 A>G polymorphisms with CRC risk in a Romanian population. A case-control study was conducted, including 156 CRC patients and 195 healthy controls. Genotyping for GAS5 and CASC8 polymorphisms was performed using real-time PCR, and the association with CRC risk was evaluated using logistic regression to calculate odds ratios (OR) and 95% confidence intervals (CI). The carriers of GAS5 rs145204276 del allele was significantly associated with increased CRC risk (OR: 2.13, 95% CI: 1.24–3.63, p = 0.005) in a dominant model. In the subgroup analysis, the association of GAS5 rs145204276 ins/del polymorphism was restricted to distal colon cancer cases (OR: 2.98, 95% CI: 1.57–5.66, p = 0.001), advanced tumor stages (III + IV) (OR: 2.54, 95% CI: 1.31–4.91, p = 0.007), and poorly differentiated tumors (G3) (OR: 3.98, 95% CI: 1.49–10.59, p = 0.009). No significant correlation was found for the CASC8 rs10505477 A>G polymorphism. GAS5 rs145204276 polymorphism may influence CRC susceptibility, particularly in distal tumors and advanced stages. However, CASC8 rs10505477 polymorphism showed no association with CRC risk in this Romanian cohort.

1. Introduction

Colorectal cancer (CRC) is a major public health concern, ranking as the third most diagnosed cancer and the second cause of cancer-related deaths worldwide. CRC accounts for approximately 1.9 million new cases and 935,000 deaths annually worldwide, thus heavily impacting healthcare systems [1,2]. Although CRC primarily affects individuals over 50 years, recent studies indicate an alarming increase in incidence among younger adults under 50 years [3]. In addition to genetic and epigenetic changes [3,4,5], several environmental factors [4,5,6,7,8] have been found to increase the risk of CRC.
Long noncoding RNAs (lncRNAs) have emerged as critical regulators in the etiology of CRC. LncRNAs are transcripts longer than 200 nucleotides with no or limited protein-coding potential and have been reported to exert regulatory effects on cellular processes such as proliferation, apoptosis, and metastasis [6,7,8,9]. LncRNAs can influence CRC cell proliferation through various mechanisms, for example, some lncRNAs act as competing endogenous RNAs (ceRNAs), sequestering microRNAs (miRNAs) and preventing them from inhibiting their target mRNAs. This results in the overexpression of oncogenes promoting cellular proliferation. Additionally, certain lncRNAs interact with chromatin-modifying complexes or transcription factors to enhance gene expression, thus driving the cell cycle forward [10,11]. One characteristic of cancer growth linked to the deregulation of lncRNAs in CRC is the avoidance of apoptosis. By modulating the expression of pro-apoptotic and anti-apoptotic genes, various lncRNAs inhibit apoptotic pathways. The overexpression of certain oncogenic lncRNAs can suppress the caspases’ activation, the central executors of apoptosis, thereby enabling cancer cells to proliferate uncontrollably and survive [12]. LncRNAs engage in CRC metastasis by regulating the epithelial-mesenchymal transition (EMT), increasing their invasive and migratory capacities. Some lncRNAs have been shown to promote EMT by interacting with signaling pathways such as Wnt/β-catenin. This interaction promotes the upregulation of mesenchymal markers and downregulation of epithelial markers, therefore aiding in the spread of cancer cells from the primary tumor to remote locations [11,13,14,15].
One notable lncRNA, Growth Arrest-Specific 5 (GAS5), has been identified as a tumor suppressor in various cancers, including CRC [16,17,18,19,20,21]. GAS5 polymorphisms, particularly rs145204276 (a 5-bp ins/del in its promoter region), affect the gene’s transcriptional activity and are associated with cancer susceptibility [22,23,24]. The deletion (del) allele of rs145204276 has been associated with a protective effect against CRC but also with increasing the risk for other types of cancer, emphasizing its complex role in tumorigenesis [25,26,27].
Another lncRNA of interest in CRC is Cancer Susceptibility Candidate 8 (CASC8), located within the region of 8q24. CASC8 plays a role in tumor progression by interacting with chromatin-modifying complexes and transcription factors. The rs10505477 polymorphism in the CASC8 intron is one of the most studied single nucleotide polymorphisms (SNPs), with studies indicating its role in CRC susceptibility [28,29,30]. In addition, CASC8 dysregulation was present in numerous cancers, including CRC, prostate cancer, and gastric cancer [28,29,31].
In addition to GAS5 and CASC8, other lncRNAs have been implicated in cancer development and progression. For instance, MALAT1 has been the subject of extensive research across multiple cancer types, including CRC [32,33,34,35]. Furthermore, HOTAIR has been identified as a crucial lncRNA in tumorigenesis and functions as a scaffold for chromatin-modifying complexes that assist with the epigenetic silencing of tumor suppressor genes. Its overexpression in cancers such as CRC is linked with poor prognosis [36,37,38]. Prostate Cancer Non-Coding RNA 1 (PRNCR1) was implicated predominantly in prostate cancer, where it modulates androgen receptor activity and induces tumor growth, recent findings show that PRNCR1 is also involved in CRC [39,40,41].
The carcinogenesis of CRC is a multistep process involving the accumulation of genetic mutations and epigenetic modifications, involving lncRNAs like GAS5 and CASC8 as important modulators in key signaling pathways like the Wnt/β-catenin and Hippo/YAP, which play a major role in tumor initiation and progression [42,43,44]. GAS5 was found to suppress CRC cell proliferation and induce apoptosis [45,46], whereas CASC8 plays a role in transcriptional regulation through its enhancer-like activity [47,48].
Genetic susceptibility to multifactorial diseases, including CRC, varies across geographic regions and ethnic groups. While numerous studies have investigated the role of SNPs in CRC risk, most data on GAS5 rs145204276 and CASC8 rs10505477 polymorphisms come from Asian populations, with limited research in European cohorts. In this respect, the aim of our study was to examine the relationship between the GAS5 rs145204276 and CASC8 rs10505477 polymorphisms and the susceptibility to CRC through a case-control study in a Romanian population (an Eastern European population), an ethnic group in which the association between these polymorphisms and CRC susceptibility has not previously been studied.

2. Results

We genotyped two lncRNA polymorphisms (GAS5 rs145204276 and CASC8 rs10505477) in a total of 351 subjects, including 156 CRC patients and 195 healthy controls. The groups were matched for age and sex, with no statistically significant differences between CRC patients and the controls (p > 0.05). The parameters and clinical characteristics of the CRC patients are presented in Table 1. The mean age was 68.61 ± 9 years for CRC patients and 66.69 ± 7.94 years for the controls. Among the CRC group, 89 were males and 67 were females. Tumor localization was as follows: 35 cases in the proximal colon, 69 in the distal colon, and 52 in the rectum.
Based on Dukes’ classification, 89 patients were classified as Stages A + B, while 67 were in Stages C + D. Tumor differentiation grades revealed 23 cases as well-differentiated (G1), 113 as moderately differentiated (G2), and 20 as poorly differentiated (G3). For each polymorphism analyzed, the genotype distributions were consistent with the expectations of Hardy–Weinberg equilibrium in the case and control groups (p > 0.05). This indicates no evidence of genetic drift or selective advantage within the case and control population, supporting the reliability of the genotyping process and the representativeness of both the case and control groups. (Table 2).

2.1. LncRNA Polymorphisms and CRC Susceptibility

For each polymorphism, the minor allele was considered the risk variant in comparison to the wild-type allele. The genotype and allele frequencies, along with their association with CRC risk, are presented in Table 3.
A significant association was observed for the GAS5 rs145204276 ins/del polymorphism in the codominant, dominant, and allelic genetic models. Individuals with the ins/del genotype showed a higher frequency among CRC patients compared to controls. The strongest association was identified in the dominant model, where the relative risk for carriers of the del allele was significantly elevated (OR: 2.13, 95% CI: 1.24–3.63, p = 0.005) compared to individuals with the wild-type genotype (ins/ins). Furthermore, a significant correlation was observed in the allelic model, when del allele was compared with the more frequent ins allele (OR: 1.99, 95% CI: 1.21–3.27, p = 0.006).
No significant association was found for the CASC8 rs10505477 A>G SNP in any of the genetic models (codominant, dominant, recessive, or allelic). The distribution of CASC8 genotypes and allele frequencies did not differ significantly between CRC patients and controls (p > 0.025).

2.2. Association of LncRNA Polymorphisms with Tumor Stage and Histological Grade

The association of lncRNA polymorphisms with tumor stage and histological grade was evaluated, with results summarized in Table 4 and Table 5. For GAS5 rs145204276, significant associations were observed between the del allele and advanced tumor stages (III + IV) (p = 0.015) as well as poorly differentiated tumors (G3) (p = 0.009). In contrast, no correlations were found between CASC8 rs10505477 A>G SNP and tumor stage, and histological grade.

2.3. LncRNA Polymorphisms and Tumor Localization

Further analysis of tumor site revealed a strong association between the GAS5 rs145204276 del allele and tumors located in the distal colon in the dominant model, with the relative risk for del carriers being 2.98 (95% CI: 1.57–5.66) compared to the more frequent ins/ins genotype. No associations were found for CASC8 rs10505477 A>G SNP relating tumor localization, including proximal versus distal CRC and rectal cancer subgroups (p > 0.025) (Table 6).

Post Hoc Power Analysis

To evaluate the robustness of our findings, a post hoc power analysis was performed based on the observed effect sizes in our study. With a sample size of 156 CRC patients and 195 healthy controls, the analysis demonstrated that our study had approximately 80% power to detect an effect size of 0.32 at a significance level of 0.05. This indicates that the sample size was adequate to identify meaningful associations between the studied polymorphisms and CRC susceptibility.

3. Discussion

In this association case-control study, we evaluated the correlation between two lncRNA polymorphisms and their potential influence on CRC susceptibility in a Romanian population and we detected an association for GAS5 rs145204276 but not for CASC8 rs10505477 [49]. These polymorphisms were selected based on their location in functional regions of lncRNA genes and their previously reported roles in modulating cancer risk [10,50,51,52,53]. By examining their distribution and association with CRC, we aimed to determine the genetic contribution of these lncRNAs to CRC pathogenesis in this specific population.
Several case-control studies have explored the association between lncRNA polymorphisms and susceptibility to CRC, some of which reported significant associations while others reported no clear link.
We found a positive association between the GAS5 rs145204276 deletion (del) allele and CRC susceptibility. In our study, the del allele was associated with an increased risk of CRC [49], suggesting that it may act as a risk factor rather than providing a protective effect. This finding contrasts with some previous evidence suggesting a tumor-suppressive role of GAS5 in certain cancers, pointing towards the complexity of lncRNA function in different tissues and disease conditions. Further, we observed no significant association between the CASC8 rs10505477 and CRC susceptibility [49], suggesting that this polymorphism may not play a major role in CRC risk within the studied population.
GAS5, a well-documented lncRNA with tumor-suppressive potential, is involved in key cellular processes such as apoptosis and proliferation [22,50,54,55,56]. GAS5 exerts its function through interactions with critical cellular pathways, including the p53 pathway and microRNAs, such as miR-21 [57,58,59,60]. GAS5 can act as a molecular sponge for various microRNAs (miRNAs), thereby modulating the expression of miRNA target genes involved in tumorigenesis. The rs145204276 polymorphism may influence the binding affinity between GAS5 and specific miRNAs, altering the regulatory networks that control cell proliferation and apoptosis. Although some previous reports have linked increased GAS5 expression to reduced cancer risk [6,50,61,62], our findings suggest that the rs145204276 del allele may enhance CRC risk in Romanian population, mainly for advanced and poorly differentiated tumors. This observation aligns with other studies reporting that GAS5 expression can have varying effects regarding metastasis, prognosis, or proliferation [6,63], also depending on the cancer type and tissue-specific regulatory mechanisms [64,65]. In a study by Tao et al., the del allele was associated with increased hepatocellular carcinoma risk due to altered GAS5 transcript activity, indicative of tissue-specific gene regulatory mechanisms [66]. Similarly, GAS5 polymorphisms have been linked to glioma progression, where GAS5 expression was dysregulated, resulting in impaired tumor suppression [67]. Such variations may result from tissue-specific regulatory mechanisms and interactions with distinct molecular pathways in different cancer types.
CASC8, located in the 8q24 chromosomal region, has also been studied for its association with cancer susceptibility, particularly in CRC. This locus is well known for harboring risk variants that regulate key oncogenic pathways, including the Wnt/β-catenin signaling pathway and the MYC oncogene, both of which play critical roles in CRC initiation and progression [28,68]. Our study did not show a statistically significant correlation in this Romanian population [49], indicating that this polymorphism may not be a strong risk factor for CRC in our cohort. While some studies linked CASC8 rs10505477 to elevated CRC risk [69,70,71,72,73], conflicting results have been reported in other populations [74,75]. For instance, Yao et al. found that rs10505477 was associated with the A allele in relation to CRC risk in certain ethnic groups, indicating a potential role for genetic background and environmental interactions in modulating CASC8-associated cancer susceptibility [74]. Interestingly, CASC8 polymorphisms have also been associated with differential cancer risks in adenomas and other cancer types. A case-control study by Gargallo et al. highlighted that CASC8 rs10505477 polymorphisms were associated with a lower risk of colorectal adenomas, suggesting that this locus may play varying roles depending on cancer subtype or disease stage [75].
There are several limitations in our study that should be noted. First, the sample size was relatively modest, which may have limited the power to detect subtle associations, particularly in subgroup analyses based on tumor location and disease stage. Second, we focused on only two lncRNA polymorphisms (GAS5 rs145204276 and CASC8 rs10505477) and did not include other potentially relevant genetic variants. Third, our study lacked functional assays to validate the biological implications of these polymorphisms, such as their effects on GAS5 and CASC8 expression or activity. Additionally, we did not account for environmental factors, including dietary habits, lifestyle, or microbiome composition, which are known to influence CRC risk. Lastly, since our study population consisted primarily of individuals of Romanian ethnicity, the findings may not be generalizable to other populations, necessitating further studies in diverse cohorts.

4. Materials and Methods

4.1. Subjects

A total of 351 individuals were included in this study, comprising of 156 patients diagnosed with CRC and 195 healthy controls. Genotyping was conducted for the GAS5 rs145204276 and CASC8 rs10505477 polymorphisms.
Patients included in the CRC group were diagnosed with sporadic colorectal adenocarcinoma, confirmed through histopathological analysis. All CRC cases were verified as having no prior history of hereditary cancer syndromes, such as familial adenomatous polyposis or Lynch syndrome (hereditary non-polyposis CRC).
Patients were excluded from the case group if they presented with metastatic colorectal adenocarcinoma originating from a primary malignancy in another organ. Additionally, individuals with a documented history of other primary malignancies were excluded to ensure the focus remained on sporadic CRC.
The control group consisted of cancer-free individuals with no personal history of CRC or other malignancies. Controls were matched to the CRC group by age and gender to ensure the comparability of the groups.
This study adhered to the ethical principles outlined in the Declaration of Helsinki https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/ (accessed on 24 January 2019), and was approved by the Ethics Committee of the University of Medicine and Pharmacy of Craiova, Romania (No. 39/18 February 2019).

4.2. Genotyping

Blood samples were collected from each participant in 6 mL EDTA tubes and stored at 4 °C until processing. Genomic DNA was extracted from peripheral blood leukocytes using the Wizard® Genomic DNA Purification Kit (Promega, Madison, WI, USA), following the manufacturer’s instructions. After extraction, DNA quantity and quality were assessed to ensure a minimum concentration of 20 ng. Absorbance readings at 260 nm and 320 nm were used to evaluate contamination, with a target absorbance ratio of at least 1.7. DNA normalization was performed to ensure uniform starting material for downstream analyses.
The GAS5 rs145204276 (ins/del) and CASC8 rs10505477 (A>G) polymorphisms were genotyped using real-time polymerase chain reaction (RT-PCR) with TaqMan predesigned probes. RT-PCR was conducted in 384-well plates on a ViiA™ 7 RT-PCR System (Life Technologies, Carlsbad, CA, USA). Before processing all samples, amplification conditions for the probes were optimized using random samples. Each plate included at least two negative controls (no DNA) to monitor for contamination.
Genotyping was performed in a reaction volume of 5 µL, comprising 2.5 µL reaction master mix, 1.125 µL ultrapure water, 0.250 µL TaqMan probe mix, and 1.125 µL of DNA extract. The thermal cycling conditions included an initial hold at 60 °C for 30 s and 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. Genotypes were determined by fluorescence detection using FAM and VIC dye labeling, with ROX used as a passive reference dye. All genotyping was conducted in a blinded manner, without knowledge of participant phenotype.

4.3. Statistical Analysis

The Hardy–Weinberg equilibrium (HWE) of the GAS5 rs145204276 and CASC8 rs10505477 polymorphisms was assessed using the goodness-of-fit chi-square (χ2) test. Logistic regression analysis was employed to evaluate the association between these polymorphisms and CRC susceptibility. The analysis was adjusted for potential confounders, including age and gender, to mitigate their impact on CRC risk. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to quantify the strength of the association under codominant, dominant, recessive, and allelic models.
The codominant model examined the risk of CRC for each genotype separately (wild-type, heterozygous, and mutant). The dominant model compared individuals carrying at least one mutant allele (heterozygous or mutant) to those with the wild-type genotype. The recessive model assessed the risk associated with carrying two mutant alleles compared to those with one or no mutant alleles. The allelic model evaluated the frequency of mutant versus wild-type alleles in cases and controls. These models provided a comprehensive analysis of the relationship between the GAS5 rs145204276 and CASC8 rs10505477 polymorphisms and CRC susceptibility under various genetic inheritance patterns.
Statistical analyses were performed using Microsoft Excel 2019 (MSO Version 2409) and SPSS Statistics for Windows, Version 22.0 (IBM SPSS Statistics, Armonk, NY, USA). The Bonferroni-corrected alpha level was set at 0.025 (0.05/2 SNPs)
Baseline characteristics of the CRC and control groups were compared using appropriate statistical tests based on the type of variable. For categorical variables, such as gender distribution, the chi-square (χ2) test was applied to determine whether there were significant differences between groups. For continuous variables, such as age, the independent t-test was used to compare the means between cases and controls. A p-value of less than 0.025 was considered statistically significant for all analyses. The minor allele frequency (MAF) for each polymorphism was calculated in both the case and control groups.

5. Conclusions

In conclusion, our study revealed that the GAS5 rs145204276 del allele is associated with an increased risk of CRC, mainly for advanced and poorly differentiated tumors, suggesting its role as a potential risk factor, while no significant association was observed for the CASC8 rs10505477 polymorphism. These findings highlight the complex and context-dependent roles of lncRNAs in cancer susceptibility. Future research involving larger, multi-ethnic cohorts and functional analyses are necessary to further explore the role of these polymorphisms and clarify the underlying molecular mechanisms.

Author Contributions

Conceptualization, C.S.M., M.S., B.P.-M., M.-G.C. and F.B.; data curation, B.C.A., G.-C.C., I.S., R.M.P. and A.-L.R.; formal analysis, B.P.-M., M.-G.C., I.D.V., C.V.O., M.C.C., R.M.P., A.-L.R. and F.B.; funding acquisition, C.S.M. and F.B.; investigation, C.S.M., I.D.V., B.C.A., C.V.O., M.C.C. and G.-C.C.; methodology, M.S, B.P.-M., M.-G.C., I.D.V., B.C.A., C.V.O., M.C.C., G.-C.C. and F.B.; project administration, C.S.M., M.S. and F.B.; software, M.-G.C., I.S., R.M.P. and A.-L.R.; supervision, C.S.M., M.S., M.-G.C. and F.B.; validation, M.-G.C., A.-L.R. and F.B.; writing—original draft, C.S.M., M.S., B.P.-M., M.-G.C. and I.S.; writing—review and editing, C.S.M., B.P.-M., M.-G.C. and F.B. All authors have read and agreed to the published version of the manuscript.

Funding

The study was supported by research grants AE 540/08.10.2018 and AE 26/41c. 11.10.2021. The Article Processing Charges were funded by the University of Medicine and Pharmacy of Craiova, Romania.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of the University of Medicine and Pharmacy of Craiova, Romania (No. 39/18 February 2019).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

All data presented here are available from the authors upon reasonable request.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Xi, Y.; Xu, P. Global colorectal cancer burden in 2020 and projections to 2040. Transl. Oncol. 2021, 14, 101174. [Google Scholar] [CrossRef]
  2. Morgan, E.; Arnold, M.; Gini, A.; Lorenzoni, V.; Cabasag, C.J.; Laversanne, M.; Vignat, J.; Ferlay, J.; Murphy, N.; Bray, F. Global burden of colorectal cancer in 2020 and 2040: Incidence and mortality estimates from GLOBOCAN. Gut 2023, 72, 338–344. [Google Scholar] [CrossRef]
  3. Hong, S.N. Genetic and epigenetic alterations of colorectal cancer. Intest. Res. 2018, 16, 327–337. [Google Scholar] [CrossRef]
  4. Schoen, R.E.; Razzak, A.; Yu, K.J.; Berndt, S.I.; Firl, K.; Riley, T.L.; Pinsky, P.F. Incidence and Mortality of Colorectal Cancer in Individuals with a Family History of Colorectal Cancer. Gastroenterology 2015, 149, 1438–1445.e1. [Google Scholar] [CrossRef]
  5. Peters, U.; Bien, S.; Zubair, N. Genetic architecture of colorectal cancer. Gut 2015, 64, 1623–1636. [Google Scholar] [CrossRef]
  6. Zheng, Y.; Song, D.; Xiao, K.; Yang, C.; Ding, Y.; Deng, W.; Tong, S. LncRNA GAS5 contributes to lymphatic metastasis in colorectal cancer. Oncotarget 2016, 7, 83727–83734. [Google Scholar] [CrossRef]
  7. Zhou, X.; Chen, H.; Zhu, L.; Hao, B.; Zhang, W.; Hua, J.; Gu, H.; Jin, W.; Zhang, G. Helicobacter pylori infection related long noncoding RNA (lncRNA) AF147447 inhibits gastric cancer proliferation and invasion by targeting MUC2 and up-regulating miR-34c. Oncotarget 2016, 7, 82770–82782. [Google Scholar] [CrossRef]
  8. Li, W.; Huang, K.; Wen, F.; Cui, G.; Guo, H.; Zhao, S. Genetic variation of lncRNA GAS5 contributes to the development of lung cancer. Oncotarget 2017, 8, 91025–91029. [Google Scholar] [CrossRef]
  9. Lin, Y.; Zhao, W.; Lv, Z.; Xie, H.; Li, Y.; Zhang, Z. The functions and mechanisms of long non-coding RNA in colorectal cancer. Front. Oncol. 2024, 14, 1419972. [Google Scholar] [CrossRef]
  10. Kadian, L.K.; Verma, D.; Lohani, N.; Yadav, R.; Ranga, S.; Gulshan, G.; Pal, S.; Kumari, K.; Chauhan, S.S. Long non-coding RNAs in cancer: Multifaceted roles and potential targets for immunotherapy. Mol. Cell. Biochem. 2024, 479, 3229–3254. [Google Scholar] [CrossRef]
  11. Zhang, J.; Meng, X.; Zhou, Y.; Jiang, Z.; Chen, H.; Meng, Z.; Zhang, Q.; Chen, W. Lnc-LRRTM4 promotes proliferation, metastasis and EMT of colorectal cancer through activating LRRTM4 transcription. Cancer Cell Int. 2023, 23, 142. [Google Scholar] [CrossRef]
  12. Irfan, M.; Javed, Z.; Khan, K.; Khan, N.; Docea, A.O.; Calina, D.; Sharifi-Rad, J.; Cho, W.C. Apoptosis evasion via long non-coding RNAs in colorectal cancer. Cancer Cell Int. 2022, 22, 280. [Google Scholar] [CrossRef]
  13. Liu, Y.; Lv, H.; Liu, X.; Xu, L.; Li, T.; Zhou, H.; Zhu, H.; Hao, C.; Lin, C.; Zhang, Y. The RP11-417E7.1/THBS2 signaling pathway promotes colorectal cancer metastasis by activating the Wnt/β-catenin pathway and facilitating exosome-mediated M2 macrophage polarization. J. Exp. Clin. Cancer Res. 2024, 43, 195. [Google Scholar] [CrossRef]
  14. Ahmad, M.; Weiswald, L.-B.; Poulain, L.; Denoyelle, C.; Meryet-Figuiere, M. Involvement of lncRNAs in cancer cells migration, invasion and metastasis: Cytoskeleton and ECM crosstalk. J. Exp. Clin. Cancer Res. 2023, 42, 173. [Google Scholar] [CrossRef]
  15. Wu, Y.; Xu, X. Long non-coding RNA signature in colorectal cancer: Research progression and clinical application. Cancer Cell Int. 2023, 23, 28. [Google Scholar] [CrossRef]
  16. Lei, Y.; Jing-jing, L.; Ke-nan, Z.; Qing-zhong, T.; Jin, L. A tumor suppressive role of lncRNA GAS5 in human colorectal cancer. Open Life Sci. 2016, 11, 105–109. [Google Scholar] [CrossRef]
  17. Ma, C.; Shi, X.; Zhu, Q.; Li, Q.; Liu, Y.; Yao, Y.; Song, Y. The growth arrest-specific transcript 5 (GAS5): A pivotal tumor suppressor long noncoding RNA in human cancers. Tumor Biol. 2016, 37, 1437–1444. [Google Scholar] [CrossRef]
  18. Yang, W.; Hong, L.; Xu, X.; Wang, Q.; Huang, J.; Jiang, L. LncRNA GAS5 suppresses the tumorigenesis of cervical cancer by downregulating miR-196a and miR-205. Tumor Biol. 2017, 39, 1010428317711315. [Google Scholar] [CrossRef]
  19. Li, G.; Qian, L.; Tang, X.; Chen, Y.; Zhao, Z.; Zhang, C. Long non-coding RNA growth arrest-specific 5 (GAS5) acts as a tumor suppressor by promoting autophagy in breast cancer. Mol. Med. Rep. 2020, 22, 2460–2468. [Google Scholar] [CrossRef]
  20. Zhang, H.; Guo, Y.; Song, Y.; Shang, C. Long noncoding RNA GAS5 inhibits malignant proliferation and chemotherapy resistance to doxorubicin in bladder transitional cell carcinoma. Cancer Chemother. Pharmacol. 2017, 79, 49–55. [Google Scholar] [CrossRef]
  21. Cai, H.; Xu, W.; Zhang, X. LncRNA growth arrest-special 5 polymorphisms and predisposition to cancer: A meta-analysis. Int. J. Biol. Markers 2020, 35, 28–34. [Google Scholar] [CrossRef]
  22. Zhao, S.; Liu, P.; Ruan, Z.; Li, J.; Zeng, S.; Zhong, M.; Tang, L. Association between long non-coding RNA (lncRNA) GAS5 polymorphism rs145204276 and cancer risk. J. Int. Med. Res. 2021, 49, 3000605211039798. [Google Scholar] [CrossRef]
  23. Tang, Y.; Wang, Y.; Wang, X.; Liu, Y.; Zheng, K. A Genetic Variant of rs145204276 in the Promoter Region of Long Noncoding RNA GAS5 Is Associated with a Reduced Risk of Breast Cancer. Clin. Breast Cancer 2019, 19, e415–e421. [Google Scholar] [CrossRef]
  24. Xiang, X.; Chen, L.; He, J.; Ma, G.; Li, Y. LncRNA GAS5 rs145204276 Polymorphism Reduces Renal Cell Carcinoma Susceptibility in Southern Chinese Population. J. Inflamm. Res. 2022, 15, 1147–1158. [Google Scholar] [CrossRef]
  25. Weng, S.L.; Ng, S.C.; Lee, Y.C.; Hsiao, Y.H.; Hsu, C.F.; Yang, S.F.; Wang, P.H. The relationships of genetic polymorphisms of the long noncoding RNA growth arrest-specific transcript 5 with uterine cervical cancer. Int. J. Med. Sci. 2020, 17, 1187–1195. [Google Scholar] [CrossRef]
  26. Zheng, Z.; Liu, S.; Wang, C.; Han, X. A Functional Polymorphism rs145204276 in the Promoter of Long Noncoding RNA GAS5 Is Associated with an Increased Risk of Ischemic Stroke. J. Stroke Cerebrovasc. Dis. 2018, 27, 3535–3541. [Google Scholar] [CrossRef]
  27. Shen, Z.; She, Q. Association Between the Deletion Allele of Ins/Del Polymorphism (Rs145204276) in the Promoter Region of GAS5 with the Risk of Atherosclerosis. Cell. Physiol. Biochem. 2018, 49, 1431–1443. [Google Scholar] [CrossRef]
  28. Cui, Z.; Gao, M.; Yin, Z.; Yan, L.; Cui, L. Association between lncRNA CASC8 polymorphisms and the risk of cancer: A meta-analysis. Cancer Manag. Res. 2018, 10, 3141–3148. [Google Scholar] [CrossRef]
  29. Hu, L.; Chen, S.H.; Lv, Q.L.; Sun, B.; Qu, Q.; Qin, C.Z.; Fan, L.; Guo, Y.; Cheng, L.; Zhou, H.H. Clinical Significance of Long Non-Coding RNA CASC8 rs10505477 Polymorphism in Lung Cancer Susceptibility, Platinum-Based Chemotherapy Response, and Toxicity. Int. J. Environ. Res. Public Health 2016, 13, 545. [Google Scholar] [CrossRef]
  30. Yang, Y.; Junjie, P.; Sanjun, C.; Ma, Y. Long non-coding RNAs in Colorectal Cancer: Progression and Future Directions. J. Cancer 2017, 8, 3212–3225. [Google Scholar] [CrossRef]
  31. Yang, L.; Tang, L.; Min, Q.; Tian, H.; Li, L.; Zhao, Y.; Wu, X.; Li, M.; Du, F.; Chen, Y.; et al. Emerging role of RNA modification and long noncoding RNA interaction in cancer. Cancer Gene Ther. 2024, 31, 816–830. [Google Scholar] [CrossRef]
  32. Yang, M.H.; Hu, Z.Y.; Xu, C.; Xie, L.Y.; Wang, X.Y.; Chen, S.Y.; Li, Z.G. MALAT1 promotes colorectal cancer cell proliferation/migration/invasion via PRKA kinase anchor protein 9. Biochim. Biophys. Acta 2015, 1852, 166–174. [Google Scholar] [CrossRef]
  33. Ji, Q.; Cai, G.; Liu, X.; Zhang, Y.; Wang, Y.; Zhou, L.; Sui, H.; Li, Q. MALAT1 regulates the transcriptional and translational levels of proto-oncogene RUNX2 in colorectal cancer metastasis. Cell Death Dis. 2019, 10, 378. [Google Scholar] [CrossRef]
  34. Zheng, H.T.; Shi, D.B.; Wang, Y.W.; Li, X.X.; Xu, Y.; Tripathi, P.; Gu, W.L.; Cai, G.X.; Cai, S.J. High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer. Int. J. Clin. Exp. Pathol. 2014, 7, 3174–3181. [Google Scholar]
  35. Shen, W.; Yu, Q.; Pu, Y.; Xing, C. Upregulation of Long Noncoding RNA MALAT1 in Colorectal Cancer Promotes Radioresistance and Aggressive Malignance. Int. J. Gen. Med. 2022, 15, 8365–8380. [Google Scholar] [CrossRef]
  36. Chen, S.; Zhang, C.; Feng, M. Prognostic Value of LncRNA HOTAIR in Colorectal Cancer: A Meta-analysis. Open Med. 2020, 15, 76–83. [Google Scholar] [CrossRef]
  37. Huang, Y.; Wang, L.; Liu, D. HOTAIR regulates colorectal cancer stem cell properties and promotes tumorigenicity by sponging miR-211-5p and modulating FLT-1. Cell Cycle 2021, 20, 1999–2009. [Google Scholar] [CrossRef]
  38. Hu, H.; Yang, H.; Fan, S.; Jia, X.; Zhao, Y.; Li, H. LncRNA HOTAIR promotes DNA damage repair and radioresistance by targeting ATR in colorectal cancer. Oncol. Res. 2024, 32, 1335–1346. [Google Scholar] [CrossRef]
  39. Yang, L.; Qiu, M.; Xu, Y.; Wang, J.; Zheng, Y.; Li, M.; Xu, L.; Yin, R. Upregulation of long non-coding RNA PRNCR1 in colorectal cancer promotes cell proliferation and cell cycle progression. Oncol. Rep. 2016, 35, 318–324. [Google Scholar] [CrossRef]
  40. Cicek, M.; Slager, S.; Achenbach, S.; French, A.; Blair, H.; Fink, S.; Foster, N.; Kabat, B.; Halling, K.; Cunningham, J.; et al. Functional and Clinical Significance of Variants Localized to 8q24 in Colon Cancer. Cancer Epidemiol. Biomark. Prev. 2009, 18, 2492–2500. [Google Scholar] [CrossRef]
  41. Li, L.; Sun, R.; Liang, Y.; Pan, X.; Li, Z.; Bai, P.; Zeng, X.; Zhang, D.; Zhang, L.; Gao, L. Association between polymorphisms in long non-coding RNA PRNCR1 in 8q24 and risk of colorectal cancer. J. Exp. Clin. Cancer Res. 2013, 32, 104. [Google Scholar] [CrossRef]
  42. Bardhan, K.; Liu, K. Epigenetics and colorectal cancer pathogenesis. Cancers 2013, 5, 676–713. [Google Scholar] [CrossRef]
  43. Tariq, K.; Ghias, K. Colorectal cancer carcinogenesis: A review of mechanisms. Cancer Biol. Med. 2016, 13, 120–135. [Google Scholar]
  44. Nguyen, L.H.; Goel, A.; Chung, D.C. Pathways of Colorectal Carcinogenesis. Gastroenterology 2020, 158, 291–302. [Google Scholar] [CrossRef]
  45. Ji, J.; Dai, X.; Yeung, S.J.; He, X. The role of long non-coding RNA GAS5 in cancers. Cancer Manag. Res. 2019, 11, 2729–2737. [Google Scholar] [CrossRef]
  46. Luo, G.; Liu, D.; Huang, C.; Wang, M.; Xiao, X.; Zeng, F.; Wang, L.; Jiang, G. LncRNA GAS5 Inhibits Cellular Proliferation by Targeting P27(Kip1). Mol. Cancer Res. 2017, 15, 789–799. [Google Scholar] [CrossRef]
  47. Wu, Q.; Zhang, H.; Yang, D.; Min, Q.; Wang, Y.; Zhang, W.; Zhan, Q. The m6A-induced lncRNA CASC8 promotes proliferation and chemoresistance via upregulation of hnRNPL in esophageal squamous cell carcinoma. Int. J. Biol. Sci. 2022, 18, 4824–4836. [Google Scholar] [CrossRef]
  48. Jiang, X.; Guan, J.; Xu, Y.; Ren, H.; Jiang, J.; Wudu, M.; Wang, Q.; Su, H.; Zhang, Y.; Zhang, B.; et al. Silencing of CASC8 inhibits non-small cell lung cancer cells function and promotes sensitivity to osimertinib via FOXM1. J. Cancer 2021, 12, 387–396. [Google Scholar] [CrossRef]
  49. Cucu, M.; Mire, C.S.; Diaconescu, M.; Gheorghe, A.; Mandache, B.P.; Burada, E.; Vilcea, A.M.; Streata, I.; Ioana, M.; Schenker, M. The GAS5 rs145204276 ins/del polymorphism is associated with increased susceptibility to colorectal cancer. In Proceedings of the 55th European Society of Human Genetics (ESHG) Conference, Vienna, Austria, 11–14 June 2022. [Google Scholar]
  50. Yang, X.; Xie, Z.; Lei, X.; Gan, R. Long non-coding RNA GAS5 in human cancer (Review). Oncol. Lett. 2020, 20, 2587–2594. [Google Scholar] [CrossRef]
  51. Ma, J.; Miao, H.; Zhang, H.; Ren, J.; Qu, S.; Da, J.; Xu, F.; Zhao, H. LncRNA GAS5 modulates the progression of non-small cell lung cancer through repressing miR-221-3p and up-regulating IRF2. Diagn. Pathol. 2021, 16, 46. [Google Scholar] [CrossRef]
  52. Ge, X.; Shen, Z.; Yin, Y. Comprehensive review of LncRNA-mediated therapeutic resistance in non-small cell lung cancer. Cancer Cell Int. 2024, 24, 369. [Google Scholar] [CrossRef]
  53. Zhang, N.; Sun, Y.; Mei, Z.; He, Z.; Gu, S. Novel insights into mutual regulation between N6-methyladenosine modification and LncRNAs in tumors. Cancer Cell Int. 2023, 23, 127. [Google Scholar] [CrossRef]
  54. Pickard, M.R.; Williams, G.T. Molecular and Cellular Mechanisms of Action of Tumour Suppressor GAS5 LncRNA. Genes 2015, 6, 484–499. [Google Scholar] [CrossRef]
  55. Lambrou, G.I.; Hatziagapiou, K.; Zaravinos, A. The Non-Coding RNA GAS5 and Its Role in Tumor Therapy-Induced Resistance. Int. J. Mol. Sci. 2020, 21, 7633. [Google Scholar] [CrossRef]
  56. Yu, Y.; Hann, S.S. Novel Tumor Suppressor lncRNA Growth Arrest-Specific 5 (GAS5) in Human Cancer. OncoTargets Ther. 2019, 12, 8421–8436. [Google Scholar] [CrossRef]
  57. Zhou, Y.; Chen, B. GAS5-mediated regulation of cell signaling (Review). Mol. Med. Rep. 2020, 22, 3049–3056. [Google Scholar] [CrossRef]
  58. Zhang, Z.; Zhu, Z.; Watabe, K.; Zhang, X.; Bai, C.; Xu, M.; Wu, F.; Mo, Y.Y. Negative regulation of lncRNA GAS5 by miR-21. Cell Death Differ. 2013, 20, 1558–1568. [Google Scholar] [CrossRef]
  59. Xie, J.; Wang, J.J.; Li, Y.J.; Wu, J.; Gu, X.J.; Yang, X.R. LncRNA GAS5 Suppresses Colorectal Cancer Progress by Target miR-21/LIFR Axis. Evid.-Based Complement. Altern. Med. 2022, 2022, 3298939. [Google Scholar] [CrossRef]
  60. Li, J.; Wang, Y.; Zhang, C.G.; Xiao, H.J.; Xiao, H.J.; Hu, J.M.; Hou, J.M.; He, J.D. Effect of long non-coding RNA Gas5 on proliferation, migration, invasion and apoptosis of colorectal cancer HT-29 cell line. Cancer Cell Int. 2018, 18, 4. [Google Scholar] [CrossRef]
  61. Li, Q.J.; Ma, G.; Guo, H.M.; Sun, S.H.; Xu, Y.; Wang, B.J. The Variant rs145204276 of GAS5 is Associated with the Development and Prognosis of Gastric Cancer. J. Gastrointestin. Liver Dis. 2018, 27, 19–24. [Google Scholar] [CrossRef]
  62. Kaur, J.; Salehen, N.; Norazit, A.; Rahman, A.A.; Murad, N.A.A.; Rahman, N.; Ibrahim, K. Tumor Suppressive Effects of GAS5 in Cancer Cells. Noncoding RNA 2022, 8, 39. [Google Scholar] [CrossRef]
  63. Yin, D.; He, X.; Zhang, E.; Kong, R.; De, W.; Zhang, Z. Long noncoding RNA GAS5 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer. Med. Oncol. 2014, 31, 253. [Google Scholar] [CrossRef]
  64. Chang, L.; Li, C.; Lan, T.; Wu, L.; Yuan, Y.; Liu, Q.; Liu, Z. Decreased expression of long non-coding RNA GAS5 indicates a poor prognosis and promotes cell proliferation and invasion in hepatocellular carcinoma by regulating vimentin. Mol. Med. Rep. 2016, 13, 1541–1550. [Google Scholar] [CrossRef]
  65. Wang, C.; Ke, S.; Li, M.; Lin, C.; Liu, X.; Pan, Q. Downregulation of LncRNA GAS5 promotes liver cancer proliferation and drug resistance by decreasing PTEN expression. Mol. Genet. Genom. 2020, 295, 251–260. [Google Scholar] [CrossRef]
  66. Tao, R.; Hu, S.; Wang, S.; Zhou, X.; Zhang, Q.; Wang, C.; Zhao, X.; Zhou, W.; Zhang, S.; Li, C.; et al. Association between indel polymorphism in the promoter region of lncRNA GAS5 and the risk of hepatocellular carcinoma. Carcinogenesis 2015, 36, 1136–1143. [Google Scholar] [CrossRef]
  67. Yuan, J.; Zhang, N.; Zheng, Y.; Chen, Y.D.; Liu, J.; Yang, M. LncRNA GAS5 Indel Genetic Polymorphism Contributes to Glioma Risk Through Interfering Binding of Transcriptional Factor TFAP2A. DNA Cell Biol. 2018, 37, 750–757. [Google Scholar] [CrossRef]
  68. Hutter, C.M.; Slattery, M.L.; Duggan, D.J.; Muehling, J.; Curtin, K.; Hsu, L.; Beresford, S.A.; Rajkovic, A.; Sarto, G.E.; Marshall, J.R.; et al. Characterization of the association between 8q24 and colon cancer: Gene-environment exploration and meta-analysis. BMC Cancer 2010, 10, 670. [Google Scholar] [CrossRef]
  69. Haerian, M.S.; Haerian, B.S.; Rooki, H.; Molanaei, S.; Kosari, F.; Obohhat, M.; Hosseinpour, P.; Azimzadeh, P.; Mohebbi, S.R.; Akbari, Z.; et al. Association of 8q24.21 rs10505477-rs6983267 haplotype and age at diagnosis of colorectal cancer. Asian Pac. J. Cancer Prev. 2014, 15, 369–374. [Google Scholar] [CrossRef]
  70. Haerian, M.S.; Baum, L.; Haerian, B.S. Association of 8q24.21 loci with the risk of colorectal cancer: A systematic review and meta-analysis. J. Gastroenterol. Hepatol. 2011, 26, 1475–1484. [Google Scholar] [CrossRef]
  71. Yang, B.; Thyagarajan, B.; Gross, M.D.; Goodman, M.; Sun, Y.V.; Bostick, R.M. Genetic variants at chromosome 8q24, colorectal epithelial cell proliferation, and risk for incident, sporadic colorectal adenomas. Mol. Carcinog. 2014, 53 (Suppl. S1), E187–E192. [Google Scholar] [CrossRef]
  72. Li, L.; Lv, L.; Liang, Y.; Shen, X.; Zhou, S.; Zhu, J.; Ma, R. Association of 8q23-24 region (8q23.3 loci and 8q24.21 loci) with susceptibility to colorectal cancer: A systematic and updated meta-analysis. Int. J. Clin. Exp. Med. 2015, 8, 21001–21013. [Google Scholar] [PubMed]
  73. Hofer, P.; Hagmann, M.; Brezina, S.; Dolejsi, E.; Mach, K.; Leeb, G.; Baierl, A.; Buch, S.; Sutterlüty-Fall, H.; Karner-Hanusch, J.; et al. Bayesian and frequentist analysis of an Austrian genome-wide association study of colorectal cancer and advanced adenomas. Oncotarget 2017, 8, 98623–98634. [Google Scholar] [CrossRef] [PubMed]
  74. Yao, K.; Hua, L.; Wei, L.; Meng, J.; Hu, J. Correlation Between CASC8, SMAD7 Polymorphisms and the Susceptibility to Colorectal Cancer: An Updated Meta-Analysis Based on GWAS Results. Medicine 2015, 94, e1884. [Google Scholar] [CrossRef] [PubMed]
  75. Gargallo, C.J.; Lanas, Á.; Carrera-Lasfuentes, P.; Ferrandez, Á.; Quintero, E.; Carrillo, M.; Alonso-Abreu, I.; García-Gonzalez, M.A. Genetic susceptibility in the development of colorectal adenomas according to family history of colorectal cancer. Int. J. Cancer 2019, 144, 489–502. [Google Scholar] [CrossRef]
Table 1. Baseline characteristics of study subjects.
Table 1. Baseline characteristics of study subjects.
VariableColorectal CancerControl
N156195
Male/female89/67143/90
Age (years), mean ± SD68.61 ± 966.69 ± 7.94
Location
  - proximal35
  - distal69
  - rectum52
Tumor stage—Dukes stage
  - A + B89
  - C + D67
Differentiation grade
  - G1—well23
  - G2—moderate113
  - G3—poor20
Table 2. Minor allele frequencies and Hardy–Weinberg equilibrium values in the control group.
Table 2. Minor allele frequencies and Hardy–Weinberg equilibrium values in the control group.
PolymorphismMAFχ2p
Control
GAS5 rs145204276 ins/del (CAAGG>-)0.070.0070.93
CASC8 rs10505477 A>G0.470.090.76
Cases
GAS5 rs145204276 ins/del (CAAGG>-)0.140.420.52
CASC8 rs10505477 A>G0.460.560.45
Table 3. Association between lncRNA polymorphisms and CRC under multiple models of inheritance.
Table 3. Association between lncRNA polymorphisms and CRC under multiple models of inheritance.
PolymorphismColorectal Cancer
(n = 156)		Control
(n = 195)		OR (95% CI)p Value
GAS5 rs145204276 ins/del (CAAGG>-)
Codominant
ins/ins115 (73.72%)167 (85.64%)Reference-
ins/del39 (25.00%)27 (13.85%)2.09 (1.22–3.62)0.007
del/del2 (1.28%)1 (0.51%)2.90 (0.26–32.41)0.36
Dominant
ins/ins115 (73.72%)167 (85.64%)Reference-
del/del + ins/del41 (26.28%)28 (14.36%)2.13 (1.24–3.63)0.005
Recessive
ins/ins + ins/del154 (98.72%)194 (99.49%)Reference-
del/del2 (1.28%)1 (0.51%)0.39 (0.03–4.42)0.437
Allelic
ins269 (86.22%)361 (92.56%)Reference-
del43 (13.78%)29 (7.44%)1.99 (1.21–3.27)0.006
CASC8 rs10505477 A>G
Codominant
AA30 (19.23%)44 (22.56%)Reference-
AG82 (52.56%)95 (48.72%)1.27 (0.73–2.19)0.40
GG44 (28.21%)56 (28.72%)1.15 (0.63–2.12)0.65
Dominant
AA30 (19.23%)44 (22.56%)Reference-
GG + AG126 (80.77%)151 (77.44%)1.22 (0.73–2.06)0.45
Recessive
AA + AG112 (71.79%)139 (71.28%)Reference-
GG44 (28.21%)56 (28.72%)0.97 (0.61–1.56)0.92
Allelic
A142 (45.51%)183 (46.92%)Reference-
G170 (54.49%)207 (53.08%)1.06 (0.79–1.43)0.71
Table 4. Association between lncRNA polymorphisms and TNM stage of colorectal cancer.
Table 4. Association between lncRNA polymorphisms and TNM stage of colorectal cancer.
PolymorphismTumor Stage
I + II (A + B = 89) (%)		OR (95% CI); pTumor Stage
III + IV (C + D = 67) (n %)		OR (95% CI); p
GAS5 rs145204276 ins/del (CAAGG>-)
ins/ins68 (76.40%)Reference47 (70.15%)Reference
ins/del21 (23.60%)1.91 (1.01–3.61); 0.04918 (26.87%)2.37 (1.20–4.67); 0.0015
del/del0 (0%)/2 (2.98%)7.11 (0.63–80.1); 0.101
del carriers21 (23.60%)1.84 (0.98–3.47); 0.0620 (29.85%)2.54 (1.31–4.91); 0.007
CASC8 rs10505477 A>G
AA16 (17.98%)Reference14 (20.90%)Reference
AG50 (56.18%)1.45 (0.74–2.82); 0.2732 (47.76%)1.06 (0.51–2.18); 0.88
GG23 (25.84%)1.13 (0.53–2.39); 0.7521 (31.34%)1.18 (0.54–2.58); 0.68
G carriers73 (82.02%)1.33 (0.70–2.51); 0.3753 (79.10%)1.10 (0.56–2.17); 0.78
Table 5. Association between lncRNA polymorphisms and colorectal cancer in the histologic grade subgroups.
Table 5. Association between lncRNA polymorphisms and colorectal cancer in the histologic grade subgroups.
G1G2G3
SNPN = 23OR (95% CI)pN = 113OR (95% CI)pN = 20OR (95% CI)p
GAS5 rs145204276
ins/ins16Reference 87Reference 12Reference0.007
ins/del62.32 (0.83–6.45)0.125251.78 (0.97–3.25)0.0684.12 (1.54–11.01)0.007
del/del110.44 (0.62–174.9)0.1311.92 (0.12–31.06)0.650//
del carriers72.61 (0.98–6.91)0.07261.78 (0.98–3.23)0.0683.98 (1.49–10.59)0.009
CASC8 rs10505477
AA3Reference 24Reference 3Reference
AG132.01 (0.54–7.40)0.27611.18 (0.65–2.13)0.5981.24 (0.31–4.88)0.76
GG71.83 (0.45–7.50)0.39280.92 (0.47–1.80)0.8092.36 (0.60–9.23)0.19
G carriers201.94 (0.55–6.84)0.27891.08 (0.62–1.89)0.79171.65 (0.46–5.89)0.42
Table 6. Association between lncRNA polymorphisms and colorectal cancer in the tumor site subgroups.
Table 6. Association between lncRNA polymorphisms and colorectal cancer in the tumor site subgroups.
PolymorphismProximal CRCDistal CRCRectal CRC
N = 35 OR (95% CI); pN = 69OR (95% CI); pN = 52OR (95% CI); p
GAS5 rs145204276
ins/ins29Reference46Reference40Reference
ins/del51.07 (0.38–2.99); 0.90222.96 (1.54–5.67); 0.001121.86 (0.87–3.98); 0.12
del/del15.76 (0.35–94.68); 0.2513.63 (0.22–59.17); 0.380/
del carriers61.23 (0.47–3.24); 0.67232.98 (1.57–5.66); 0.001121.79 (0.84–3.82); 0.14
CASC8 rs10505477
AA7Reference13Reference10Reference
AG191.26 (0.49–3.21); 0.63371.32 (0.64–2.73); 0.45261.20 (0.53–2.71); 0.65
GG91.01 (0.35–2.93); 0.98191.15 (0.51–2.56); 0.74161.26 (0.52–3.04); 0.61
G carriers281.17 (0.48–2.85); 0.73561.26 (0.63–2.50); 0.51421.22 (0.57–2.64); 0.60
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Mirea, C.S.; Schenker, M.; Petre-Mandache, B.; Cucu, M.-G.; Camen, G.-C.; Vîlcea, I.D.; Albu, B.C.; Obleagă, C.V.; Ciorbagiu, M.C.; Streață, I.; et al. GAS5 rs145204276 Ins/Del Polymorphism Is Associated with CRC Susceptibility in a Romanian Population. Int. J. Mol. Sci. 2025, 26, 3078. https://doi.org/10.3390/ijms26073078

AMA Style

Mirea CS, Schenker M, Petre-Mandache B, Cucu M-G, Camen G-C, Vîlcea ID, Albu BC, Obleagă CV, Ciorbagiu MC, Streață I, et al. GAS5 rs145204276 Ins/Del Polymorphism Is Associated with CRC Susceptibility in a Romanian Population. International Journal of Molecular Sciences. 2025; 26(7):3078. https://doi.org/10.3390/ijms26073078

Chicago/Turabian Style

Mirea, Cecil Sorin, Michael Schenker, Bianca Petre-Mandache, Mihai-Gabriel Cucu, Georgiana-Cristiana Camen, Ionică Daniel Vîlcea, Bogdan Cristian Albu, Cosmin Vasile Obleagă, Mihai Călin Ciorbagiu, Ioana Streață, and et al. 2025. "GAS5 rs145204276 Ins/Del Polymorphism Is Associated with CRC Susceptibility in a Romanian Population" International Journal of Molecular Sciences 26, no. 7: 3078. https://doi.org/10.3390/ijms26073078

APA Style

Mirea, C. S., Schenker, M., Petre-Mandache, B., Cucu, M.-G., Camen, G.-C., Vîlcea, I. D., Albu, B. C., Obleagă, C. V., Ciorbagiu, M. C., Streață, I., Pleșea, R. M., Riza, A.-L., & Burada, F. (2025). GAS5 rs145204276 Ins/Del Polymorphism Is Associated with CRC Susceptibility in a Romanian Population. International Journal of Molecular Sciences, 26(7), 3078. https://doi.org/10.3390/ijms26073078

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop